Study Treatment
GENITAL INFECTIONS
The study drug (empagliflozin [10 mg]) and matching placebo (one tablet) were commenced on site once daily in the investigator’s presence on the day of the randomization visit (visit 2). Treatment compliance was assessed by staff during all follow-up visits, and safety monitoring of blood pressure and urine assessment for urinary tract or genital infections were performed. All patients and staff involved in the conduct of the trial were blinded to the assigned treatments.